# Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)

> **NCT03544736** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Oslo University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** Radiotherapy
- **DRUG:** Chemotherapy
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT03544736
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-26
- **Primary completion:** 2025-12-31
- **Final completion:** 2040-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03544736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03544736, "Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03544736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*